A Long-term Trial of EB-1020 in Pediatric Patients With ADHD

NCT07087327 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit Hyperactivity Disorder(ADHD)

Interventions

DRUG: EB-1020 (Centanafadine) low dose
DRUG: EB-1020 (Centanafadine) high dose

Sponsor

Otsuka Pharmaceutical Co., Ltd.